Preclinical studies using native GLP-1 or GLP-1RA have provided convincing evidence of its cardioprotective benefits, while clinical trials have shown positive effects on hypertension and dyslipidemia in patients with T2DM [3]
Keep weight loss at about 0.5%1% of body weight per week rather than losing too quickly
SGLT2 inhibitors may improve metabolic profiles in selected non-pregnant patients, but any such use must remain strictly outside pregnancy, under reliable contraception, and with guideline-consistent discontinuation before conception attempts because of urogenital adverse effects and contraindications during pregnancy (155, 156)
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal phase 3 trials in adults with obesity (ATTAIN-1)
But the picture of weight loss medications for people with eating disorders and disordered eating patterns may be more complex than it seems
I have seen a case of that in our clinic
